Technical Analysis for LPCN - Lipocine Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Historical LPCN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Outside Day | Range Expansion | -4.26% | |
| Wide Bands | Range Expansion | -4.26% | |
| Down 3 Days in a Row | Weakness | -4.26% | |
| Calm After Storm | Range Contraction | -11.76% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/04/2020
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
Chemistry Health Pharmaceutical Pharmaceutical Products Clinical Trial Alcohols Design Of Experiments Clinical Research Bypass Ketones Androstanes Testosterone Testosterone Replacement Therapy
Chemistry Health Pharmaceutical Pharmaceutical Products Clinical Trial Alcohols Design Of Experiments Clinical Research Bypass Ketones Androstanes Testosterone Testosterone Replacement Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.45 |
| 52 Week Low | 0.32 |
| Average Volume | 1,342,972 |
| 200-Day Moving Average | 1.76 |
| 50-Day Moving Average | 0.42 |
| 20-Day Moving Average | 0.45 |
| 10-Day Moving Average | 0.49 |
| Average True Range | 0.06 |
| ADX | 32.42 |
| +DI | 29.47 |
| -DI | 21.93 |
| Chandelier Exit (Long, 3 ATRs ) | 0.44 |
| Chandelier Exit (Short, 3 ATRs ) | 0.51 |
| Upper Bollinger Band | 0.57 |
| Lower Bollinger Band | 0.33 |
| Percent B (%b) | 0.5 |
| BandWidth | 52.20 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.0208 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.50 | ||||
| Resistance 3 (R3) | 0.50 | 0.48 | 0.49 | ||
| Resistance 2 (R2) | 0.48 | 0.47 | 0.48 | 0.48 | |
| Resistance 1 (R1) | 0.47 | 0.46 | 0.46 | 0.47 | 0.48 |
| Pivot Point | 0.45 | 0.45 | 0.45 | 0.45 | 0.45 |
| Support 1 (S1) | 0.44 | 0.44 | 0.43 | 0.44 | 0.42 |
| Support 2 (S2) | 0.42 | 0.43 | 0.42 | 0.42 | |
| Support 3 (S3) | 0.41 | 0.42 | 0.41 | ||
| Support 4 (S4) | 0.41 |
